Lonza is investing CHF 85 million ($94 million) in its Capsules and Health Ingredients (CHI) Division to expand its overall capsule production capacity by 30 billion capsules annually across eight sites. The investment will allow a 15% increase in CHI’s current capsule production capacity.

This latest commitment follows an investment initiated in 2019 to increase CHI’s capacity by 10 billion capsules. The addition of manufacturing capacity for a further 30 billion capsules will address the high growth across CHI’s gelatin, vegetarian, and specialty polymers portfolio as well as the liquid-filled hard capsules sold under the Licaps brand.

The investment will be made over two fiscal years, 2020 and 2021, across eight global Lonza manufacturing sites: Bornem, Belgium; Colmar, France; Greenwood, South Carolina; Haryana, India; Jakarta, Indonesia; Puebla, Mexico; Sagamihara, Japan; and Suzhou, China.

Source: Lonza